Equities Analysts Issue Forecasts for Prestige Consumer Healthcare Inc.’s Q3 2026 Earnings (NYSE:PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Investment analysts at Zacks Research boosted their Q3 2026 earnings per share estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Thursday, May 2nd. Zacks Research analyst R. Department now forecasts that the company will earn $1.20 per share for the quarter, up from their previous forecast of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2026 earnings at $4.76 EPS.

Several other research analysts have also recently issued reports on PBH. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, February 10th. TheStreet upgraded Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, February 12th. One equities research analyst has rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $110.00.

Prestige Consumer Healthcare Stock Performance

Shares of NYSE:PBH opened at $69.95 on Monday. The firm’s 50 day simple moving average is $71.12 and its 200-day simple moving average is $64.80. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09. Prestige Consumer Healthcare has a one year low of $55.96 and a one year high of $75.31. The firm has a market cap of $3.47 billion, a PE ratio of -42.65, a price-to-earnings-growth ratio of 1.90 and a beta of 0.53.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 8th. The company reported $1.06 EPS for the quarter, topping analysts’ consensus estimates of $1.04 by $0.02. Prestige Consumer Healthcare had a negative net margin of 7.11% and a positive return on equity of 14.09%. The firm had revenue of $282.74 million for the quarter, compared to analysts’ expectations of $280.25 million. During the same period in the prior year, the business posted $1.04 earnings per share. The business’s revenue for the quarter was up 2.6% on a year-over-year basis.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 5,336 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $69.00, for a total transaction of $368,184.00. Following the sale, the senior vice president now owns 15,934 shares of the company’s stock, valued at approximately $1,099,446. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.60% of the stock is currently owned by insiders.

Institutional Trading of Prestige Consumer Healthcare

Several hedge funds have recently modified their holdings of PBH. Sequoia Financial Advisors LLC grew its position in shares of Prestige Consumer Healthcare by 1.8% in the 3rd quarter. Sequoia Financial Advisors LLC now owns 10,068 shares of the company’s stock worth $576,000 after buying an additional 179 shares during the last quarter. Pacer Advisors Inc. grew its holdings in Prestige Consumer Healthcare by 85.7% in the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock worth $27,000 after purchasing an additional 204 shares during the last quarter. Parallel Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 42.5% during the fourth quarter. Parallel Advisors LLC now owns 714 shares of the company’s stock worth $44,000 after purchasing an additional 213 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of Prestige Consumer Healthcare by 7.5% during the 4th quarter. M&T Bank Corp now owns 4,139 shares of the company’s stock valued at $253,000 after purchasing an additional 289 shares during the last quarter. Finally, Swiss National Bank boosted its position in shares of Prestige Consumer Healthcare by 0.3% in the 1st quarter. Swiss National Bank now owns 97,900 shares of the company’s stock worth $7,104,000 after purchasing an additional 300 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.